Caiping Yao, Ph.D. - Publications
Affiliations: | 2001 | University of Washington, Seattle, Seattle, WA |
Year | Citation | Score | |||
---|---|---|---|---|---|
2008 | Levy R, Ragueneau-Majlessi I, Solanki B, Zannikos P, Yao C, Novak G. Pharmacokinetics, safety, and tolerability of the new antiepileptic carisbamate in the elderly. Epilepsy Research. 79: 22-30. PMID 18280116 DOI: 10.1016/J.Eplepsyres.2007.12.013 | 0.382 | |||
2003 | Levy RH, Hachad H, Yao C, Ragueneau-Majlessi I. Relationship between extent of inhibition and inhibitor dose: literature evaluation based on the metabolism and transport drug interaction database. Current Drug Metabolism. 4: 371-80. PMID 14529369 DOI: 10.2174/1389200033489325 | 0.43 | |||
2003 | Yao C, Kunze KL, Trager WF, Kharasch ED, Levy RH. Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 31: 565-71. PMID 12695344 DOI: 10.1124/Dmd.31.5.565 | 0.474 | |||
2002 | Yao C, Levy RH. Inhibition-based metabolic drug-drug interactions: predictions from in vitro data. Journal of Pharmaceutical Sciences. 91: 1923-35. PMID 12210040 DOI: 10.1002/Jps.10179 | 0.456 | |||
2001 | Yao C, Kunze KL, Kharasch ED, Wang Y, Trager WF, Ragueneau I, Levy RH. Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. Clinical Pharmacology and Therapeutics. 70: 415-24. PMID 11719727 DOI: 10.1067/Mcp.2001.119724 | 0.48 | |||
1999 | Yao CP, Mather GG, Stephens JR, Levy RH. Cytotoxicity induced by the combination of valproic acid and tumor necrosis factor-alpha: implication for valproic acid-associated hepatotoxicity syndrome. Biochemical Pharmacology. 58: 455-9. PMID 10424764 DOI: 10.1016/S0006-2952(99)00108-2 | 0.4 | |||
Show low-probability matches. |